[{"orgOrder":0,"company":"Mundipharma","sponsor":"Biosolution","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Chondrocytes","moa":"","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Mundipharma \/ Biosolution Co. Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Mundipharma \/ Biosolution Co. Ltd"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Samsung Bioepis","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"Adalimumab","moa":"TNF alpha","graph1":"Immunology","graph2":"Approved","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mundipharma \/ Samsung Bioepis","highestDevelopmentStatusID":"12","companyTruncated":"Mundipharma \/ Samsung Bioepis"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Povidone-Iodine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gargle And Mouthwash","sponsorNew":"Mundipharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mundipharma \/ Not Applicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Canagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mundipharma \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Mundipharma \/ Janssen Pharmaceutical"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tinostamustine","moa":"HDAC","graph1":"Oncology","graph2":"Phase I","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mundipharma \/ Not Applicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Rezafungin","moa":"? (1, 3)-D- glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Cidara Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharma \/ Cidara Therapeutics"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Rezafungin","moa":"? (1, 3)-D- glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Mundi Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Mundipharma \/ Mundi Pharma"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Rezafungin","moa":"? (1, 3)-D- glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Cidara Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharma \/ Cidara Therapeutics"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Rezafungin","moa":"? (1, 3)-D- glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Mundipharma","highestDevelopmentStatusID":"12","companyTruncated":"Mundipharma \/ Mundipharma"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Rezafungin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Cidara Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharma \/ Cidara Therapeutics"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Rezafungin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mundipharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharma \/ Not Applicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Peptide","year":"2022","type":"Licensing Agreement","leadProduct":"Rezafungin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mundipharma","amount2":0.56999999999999995,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.56999999999999995,"dosageForm":"Injectable\/Injection","sponsorNew":"Mundipharma \/ Mundipharma","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharma \/ Mundipharma"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Rezafungin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mundipharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharma \/ Not Applicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Rezafungin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mundipharma \/ Cidara Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Mundipharma \/ Cidara Therapeutics"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Peptide","year":"2024","type":"Partnership","leadProduct":"Rezafungin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mundipharma","amount2":0.56999999999999995,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.56999999999999995,"dosageForm":"Infusion","sponsorNew":"Mundipharma \/ Mundipharma","highestDevelopmentStatusID":"12","companyTruncated":"Mundipharma \/ Mundipharma"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Rezafungin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mundipharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mundipharma \/ Not Applicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Vectura Ltd","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Fluticasone Propionate","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Mundipharma \/ Vectura Ltd","highestDevelopmentStatusID":"12","companyTruncated":"Mundipharma \/ Vectura Ltd"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Divestment","leadProduct":"Rezafungin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mundipharma \/ Mundipharma","highestDevelopmentStatusID":"12","companyTruncated":"Mundipharma \/ Mundipharma"}]

Find Clinical Drug Pipeline Developments & Deals by Mundipharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Through the divestment, Mundipharma received the rights for Rezzayo (rezafungin acetate), an echinocandin antifungal, approved for the treatment of invasive candidiasis in adults.

                          Brand Name : Rezzayo

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 24, 2024

                          Lead Product(s) : Rezafungin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Recipient : Cidara Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Divestment

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Two companies have a collaboration agreement to develop an environmentally friendly propellant for flutiform® (fluticasone propionate/formoterol fumarate) in a pMDI formulation.

                          Brand Name : Flutiform

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 16, 2024

                          Lead Product(s) : Fluticasone Propionate,Formoterol Fumarate

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Approved

                          Sponsor : Vectura Ltd

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The payment triggered under the agreement is following the European approval of Rezzayo (rezafungin acetate), a novel, once-weekly echinocandin antifungal approved for invasive candidiasis in adults.

                          Brand Name : Rezzayo

                          Molecule Type : Peptide

                          Upfront Cash : $39.0 million

                          February 12, 2024

                          Lead Product(s) : Rezafungin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Recipient : Cidara Therapeutics

                          Deal Size : $568.0 million

                          Deal Type : Partnership

                          blank

                          04

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Rezzayo (rezafungin) is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis.

                          Brand Name : Rezzayo

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 22, 2023

                          Lead Product(s) : Rezafungin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Rezafungin is a novel once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as invasive candidiasis and candidemia.

                          Brand Name : Rezzayo

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 13, 2023

                          Lead Product(s) : Rezafungin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Cidara Therapeutics

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : CD101 (rezafungin) is a novel, once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections,demonstrated non-inferiority to the current standard of care in the treatment of candidemia and/or invasive candidi...

                          Brand Name : CD101

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          November 16, 2022

                          Lead Product(s) : Rezafungin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Rezafungin is a novel once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis.

                          Brand Name : CD101

                          Molecule Type : Peptide

                          Upfront Cash : $30.0 million

                          October 04, 2022

                          Lead Product(s) : Rezafungin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Recipient : Cidara Therapeutics

                          Deal Size : $568.0 million

                          Deal Type : Licensing Agreement

                          blank

                          08

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : European Medicines Agency filing is supported by the pivotal ReSTORE Phase III clinical trial results, where rezafungin (echinocandin/CD101) demonstrated non-inferiority to the current standard of care, caspofungin in the treatment of candidemia and/or i...

                          Brand Name : CD101

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          August 22, 2022

                          Lead Product(s) : Rezafungin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Results from ReSTORE showed primary endpoints were met with, 23.7% all-cause mortality on day 30 for rezafungin compared to 21.3% for caspofungin global cure on day 14 of 59.1% for rezafungin and 60.6% for caspofungin.

                          Brand Name : CD101

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          April 25, 2022

                          Lead Product(s) : Rezafungin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Cidara Therapeutics

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Result, did not demonstrate highly potent antifungal properties of CD101 against Candida in preclinical animal models of VVC, CD101 IV has enhanced potency and is only once-weekly therapy intended for treatment and prevention of life-threatening invasive...

                          Brand Name : CD101

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          April 14, 2022

                          Lead Product(s) : Rezafungin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Recipient : Cidara Therapeutics

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank